Amifostine (trihydrate)

Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action[1][2][3][4].

Product Specifications

CAS Number

[112901-68-5]

Product Name Alternative

WR2721 (trihydrate)

UNSPSC

12352211

Hazard Statement

H302

Target

HIF/HIF Prolyl-Hydroxylase; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/amifostine-trihydrate.html

Purity

99.95

Solubility

H2O : 70 mg/mL (ultrasonic)

Smiles

OP(SCCNCCCN)(O)=O.[H]O[H].[H]O[H].[H]O[H]

Molecular Formula

C5H21N2O6PS

Molecular Weight

268.27

Precautions

H302

References & Citations

[1]D Maurici, et al. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene. 2001 Jun 14;20 (27) :3533-40.|[2]Efstathia Giannopoulou, et al. Amifostine inhibits angiogenesis in vivo. J Pharmacol Exp Ther. 2003 Feb;304 (2) :729-37.|[3]Michael I Koukourakis, et al. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol. 2004 Jan;53 (1) :8-14.|[4]John R Kouvaris, et al. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007 Jun;12 (6) :738-47.|[5]Shao-Ze Wu, et al. Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress. Oxid Med Cell Longev. 2017;2017:4130824.